daily oral glp-1 receptor agonist orforglipron for adults with obesity Obesity: Oral GLP-1 Therapy for Obesity

FDA has only evaluated this drug for use under the chin

The primary mechanisms of action include: Enhanced insulin secretion : GLP-1 receptor agonists stimulate glucose-dependent insulin release from pancreatic beta cells, meaning insulin is released only when blood glucose levels are elevated, reducing hypoglycemia risk when used as monotherapy (though risk increases when combined with insulin or sulfonylureas)

Are DSIP side effects known

For many patients who experience fatigue when starting GLP-1 therapy, symptoms often improve as the body adapts to the medication

For most people, a sore arm or mild swelling after a flu shot is temporary

As a powerful antioxidant, glutathione helps protect our cells from damage caused by oxidative stress, which is linked to various chronic diseases and the aging process